Full-Time
Senior CRA / CRA II
Icon
10,001+ employees
Consulting and development services for pharmaceuticals
No salary listed
Senior
Burlington, ON, Canada
Remote
Must be located in Western Canada
- Bachelor's degree in a scientific or healthcare-related field.
- Oncology experience required.
- Must be located in Western Canada.
- Minimum of 2 years of experience as a Clinical Research Associate.
- In-depth knowledge of clinical trial processes, regulations, and ICH-GCP guidelines.
- Strong organizational and communication skills, with attention to detail.
- Ability to work independently and collaboratively in a fast-paced environment.
- Conducting site qualification, initiation, monitoring, and close-out visits for clinical trials.
- Ensuring protocol compliance, data integrity, and patient safety throughout the trial process.
- Collaborating with investigators and site staff to facilitate smooth study conduct.
- Performing data review and resolution of queries to maintain high-quality clinical data.
- Contributing to the preparation and review of study documentation, including protocols and clinical study reports.
Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon has a global team of experts who specialize in various therapeutic areas, allowing them to offer tailored solutions to meet the specific needs of their clients. The company's goal is to support the development of life-saving products and improve the quality of life for patients.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Simplify's Take
What believers are saying
- Increased use of AI accelerates clinical trial participant identification.
- Partnership with Mural Health enhances trial participant and site experience.
- Centre for Obesity expedites obesity-related clinical trials.
What critics are saying
- Complexity of multi-indication trials may lead to inefficiencies.
- Securities fraud lawsuit could cause financial and reputational damage.
- Underutilization of biomarkers may hinder optimization of neurodegenerative trials.
What makes Icon unique
- ICON offers a global network of offices in 53 countries.
- The company focuses on reducing time to market, cost, and increasing quality.
- ICON has extensive experience in a broad range of therapeutic areas.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Company News
At Bio€quity Europe 2025, the premier investor conference for European biopharma, ICON was proud to contribute to the conversation shaping the future of early-stage innovation.
Alongside the whitepaper, ICON has launched their new Centre for Obesity that delivers expertise and market intelligence with a ready-to-deploy infrastructure of 100 sites and an in-development database of 10,000 pre-screened patients across the breadth of comorbidities related to obesity.
Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process
After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.
ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.